Dr. Paul Sugarbaker

As one of the world’s top oncological surgeons, Dr. Paul Sugarbaker has cultivated a career focused solely on treating abdominal cancers. Today, he is one of the top peritoneal mesothelioma specialists known for his innovative, life-extending treatments. He is recognized for his dedication to increasing survival rates and decreasing recurrence in peritoneal mesothelioma patients.

“It’s what the surgeon doesn’t see that kills the patient.” —Dr. Paul Sugarbaker.

Since Dr. Sugarbaker’s initial discovery, he has dedicated the rest of his career to refining the technique in an attempt to find the perfect treatment for all peritoneal mesothelioma patients. He is known as a “last hope” for late-stage peritoneal mesothelioma patients because of his willingness to treat patients who have been turned away by other surgeons.

“I think [mesothelioma] can be cured. I’m convinced it can be cured. There will be a cure.” —Dr. Paul Sugarbaker.

Dr. Paul Sugarbaker’s Location

Sugarbaker Oncology

106 Irving St., NW #3900

Washington, DC 20010

MedStar Washington Cancer Institute

110 Irving St NW,

Washington, DC 20010


Dr. Paul Sugarbaker’s Career Highlights

  • Considered one of the world’s top authorities on mesothelioma
  • Invented the “Sugarbaker Procedure” to treat peritoneal mesothelioma
  • Director of Gastrointestinal Malignancies at MedStar Washington Hospital Center
  • Published more than 900 articles and book chapters

Dr. Paul Sugarbaker’s Background

Dr. Paul Sugarbaker received his MD from Cornell University Medical College in New York before completing a surgical residency at Peter Bent Brigham Hospital, now known as Brigham and Women’s Hospital, in Boston. Dr. Sugarbaker then completed a Masters in Immunology at the Harvard School of Arts and Science.

In 1976, Dr. Sugarbaker began working at the surgery branch of the National Cancer Institute as a Senior Investigator. He stayed in this position for the next decade, gaining invaluable cancer research experience while working as a senior surgeon.

Dr. Sugarbaker worked at the Emory Clinic in Atlanta for a short while, then moved into his Medical Director position at the Washington Cancer Institute at MedStar Washington Hospital Center in 1989. He has held this position ever since. In 1993, Dr. Sugarbaker became Chief of the Peritoneal Surface Malignancy program at the Washington Hospital Center and is now Director for their Center for Gastrointestinal Malignancies as well.

Dr. Sugarbaker is the brother of the late Dr. David Sugarbaker, a renowned pleural mesothelioma specialist.

Medical Specializations

Dr. Sugarbaker is a surgical oncologist who specializes in rare malignancies and cancers, including mesothelioma, colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei. He is a talented gastrointestinal surgeon and is best known for his work treating peritoneal mesothelioma with cytoreductive surgery and heated chemotherapy.

Dr. Sugarbaker also actively researches cancer and is the primary investigator at MedStar Washington Hospital Center, overseeing the hospital’s clinical trials and research initiatives. All of his research focuses on peritoneal metastases, which are cancers that spread on the surface of the abdominal cavity and include mesothelioma.

Dr. Sugarbaker is board-certified in general surgery.

Dr. Paul Sugarbaker’s Career Accomplishments

Dr. Sugarbaker has led an extraordinary career and has a strong paper trail to prove it. In addition to having over 900 published articles and book chapters, he has edited seven books and created two dozen videos. His professional work has taken him all across the world to every continent, and he has received four honorary professorships.

However, Dr. Sugarbaker is best known for his contributions toward the treatment of mesothelioma and other abdominal conditions. In fact, he is world-famous for the development of his “Sugarbaker Procedure”, a treatment protocol that combines traditional surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), also known as heated chemotherapy.

“Heated drugs can be augmented in their activity from 20% to 30% up to 1,000%. We try to use the more heat-augmented drugs, like mitomycin, cisplatin, and doxorubicin. We use those in the peritoneal cavity,” said Dr. Sugarbaker. This protocol has extended the lives of cancer patients from across the globe and was a massive step forward in treating cancers that infect thoracic tissues.

Awards & Honours

  • Compassionate Doctors
  • America’s Top Doctors
  • America’s Top Doctors for Cancer
  • Top Doctors: Washington DC Area
  • Top Doctors: Washington-Baltimore
  • Distinguished Service Award by the American Society of Abdominal Surgeons
  • Doctor Honoris Causa at the Universite de Liege
  • Honorary Professor at Universidad Nacional de Cordoba in Argentina
  • Merium Ann Simone Distinguished Service Award – International Spirit of Life Foundation
  • E. T. Krementz Award for Best Research Development
  • Who’s Who
  • ACS Fellow

Dr. Paul Sugarbaker’s Current Work

Dr. Paul Sugarbaker currently holds several titles, including Director of the Center of Gastrointestinal Malignancies and the Chief of Peritoneal Surface Malignancies at MedStar Washington Hospital Center. Dr. Sugarbaker also operates Sugarbaker Oncology (his own medical practice) out of the Hospital Center.

In addition to continuing to treat patients, Dr. Sugarbaker is endlessly searching for ways to better refine the Sugarbaker Procedure to produce optimal results for all patients. He believes there is a cure for cancers like mesothelioma and is maintaining his lifelong quest to try to discover it.

Dr. Sugarbaker’s ongoing research spans a number of abdominal cancers with a prominent focus on peritoneal mesothelioma. He is also interested in the way cancer spreads to secondary locations in the body and how it can occur in large regions throughout the body, called carcinomatosis.

Notable Work by Dr. Paul Sugarbaker

In his ongoing attempt to refine the Sugarbaker Procedure and find a cure for epithelial peritoneal mesothelioma, Dr. Sugarbaker researched the effectiveness of three different protocols. His study reviewed the survival rates of 129 patients, evaluating each protocol to determine the best treatment option for mesothelioma patients.

Each protocol begins with cytoreductive surgery where as much visible tumor is removed as possible. For the first protocol, cytoreductive surgery was followed by heated chemotherapy (HIPEC) immediately following the surgery.

In the second protocol, early postoperative intraperitoneal chemotherapy (EPIC) was added for 5 days after the HIPEC procedure. With EPIC, additional chemotherapy is applied to the abdomen, essentially extending the localized chemo treatment.

For the third protocol, HIPEC and EPIC were followed by NIPEC, a regional chemotherapy that is delivered locally through a port in the abdomen.

While the study noted that the combination of HIPEC and EPIC was not significantly more effective than HIPEC alone, the survival rates greatly increased when the protocol including NIPEC was used. In fact, approximately half of patients lived for 5 years after HIPEC and EPIC, while 75% of patients who received additional NIPEC were alive.

This increase in survival rates is extraordinarily promising for mesothelioma patients, as it suggests that mesothelioma may not be a fatal disease for some patients. In fact, survival rates of mesothelioma patients are likely to continue to increase as time goes on and cancer research continues.

Dr. Paul Sugarbaker’s Healing Philosophy

Dr. Paul Sugarbaker takes an aggressive approach to curing peritoneal conditions, including mesothelioma, and he’s known for taking risks that could potentially extend his patients’ lives. In fact, the HIPEC procedure was initially a highly controversial one due to its intense, postoperative nature. Two decades later, it has become a fairly common treatment for mesothelioma patients.

Outside of the operating room, Dr. Sugarbaker is also extraordinarily ambitious in his endless quest to cure peritoneal cancers and is constantly trying to refine the medical procedures that could potentially lead to a cure. Now in his 70’s, he shows no signs of slowing down in this mission. Yet, Dr. Sugarbaker still puts the patient first, and believes that personalized care and treatment strategies have to be determined on an individual level.

Mesothelioma Support Team

Mesothelioma Hope was founded by a team of advocates to educate people about this aggressive form of cancer. Mesothelioma affects thousands of people each year. We help give hope to those impacted by mesothelioma.

View 8 References
  1. Paul Sugarbaker

  2. Surgical Services

  3. https://www.medscape.com/viewarticle/806289?pa=vKvgy9Af1N5qbqKr8DdVI002b4jSrhtNeHGXKsXQaTIEIXhOsJT4GTlQ%2BoRPhz15X8MwC0EECwzp432Skuf9qw%3D%3D#vp_2

  4. Sugarbaker Oncology. “Dr. Paul H. Sugarbaker, FACS, FRCS.” Retrieved from https://www.sugarbakeroncology.com/. Accessed on December 17th, 2017.

  5. US Health News. “Dr. Paul Sugarbaker.” Retrieved from https://health.usnews.com/doctors/paul-sugarbaker-10400. Accessed on December 17th, 2017.

  6. The Washington Post. “Surgeon performs controversial cancer surgery named after him.” Retrieved from https://www.washingtonpost.com/lifestyle/style/surgeon-performs-controversial-cancer-surgery-named-after-him/2012/11/25/c8ad7ab8-29da-11e2-bab2-eda299503684_story.html?utm_term=.b8597a4efe71. Accessed on December 18th, 2017.

  7. PMP Pals. “Paul H Sugarbaker, MD, FACS, FRCS.” Retrieved from https://www.pmppals.org/www.pmppals.org/dr-paul-h-sugarbaker.html. Accessed on December 18th, 2017.

  8. The ASCO Post. “‘Hot Chemotherapy’ Generates Heated Debate about Its Use with Cytoreductive Surgery to Manage Peritoneal Metastases.” Retrieved from https://www.ascopost.com/issues/october-15-2011/hot-chemotherapy-generates-heated-debate-about-its-use-with-cytoreductive-surgery-to-manage-peritoneal-metastases.aspx. Accessed on December 19th, 2017.

Call 866-608-8933

Give us a call now to get more information and discuss your options with our team of medical and legal professionals.

Call now to discuss your medical and legal options with a patient advocate.